查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992820

乾眼症治療市場：2026-2030年全球市場預測（按劑型、藥物類型、治療類型、最終用戶、治療持續時間和分銷管道分類）

Dry Eye Medication Market by Product Form, Drug Type, Medication Type, End-user, Treatment Duration, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年乾眼症治療市場價值為 51.6 億美元，預計到 2025 年將成長至 54.9 億美元，複合年成長率為 6.72%，到 2030 年將達到 76.2 億美元。

主要市場統計數據
基準年 2024 51.6億美元
預計年份：2025年 54.9億美元
預測年份 2030 76.2億美元
複合年成長率 (%) 6.72%

為全面概述乾眼症治療奠定基礎，重點在於患者需求、技術進步和監管趨勢。

近年來，受電子螢幕使用增加、環境壓力以及全球人口老化等因素的影響，乾眼症的盛行率急劇上升。隨著患者越來越尋求緩解眼睛不適的方法，乾眼症治療市場已成為製藥創新和醫療保健投資的重點。本文首先概述了乾眼症的潛在風險因素，然後介紹了當前的市場格局，並揭示了從瞼板腺功能障礙到淚膜不穩定等多種病因如何推動臨床和商業性需求。

前所未有的創新和數位融合正在推動乾眼症治療方案和市場發展的新浪潮。

乾眼症治療市場正經歷著變革性的轉變，治療模式和市場結構正在重塑。新型藥物遞送平台，例如微乳劑眼藥水和緩釋型眼內植入物，無需頻繁用藥即可提供持續緩解，從而顯著提高了患者的依從性。同時，從智慧型手機淚液分析儀到遠端監測平台等數位健康工具的整合，使得即時收集患者數據成為可能，有助於制定更個人化的治療方案。

評估 2025 年美國關稅對乾眼症治療供應鏈、製造成本和全球貿易趨勢的連鎖反應。

2025年，美國新關稅的實施給乾眼症藥物的整個供應鏈帶來了巨大的成本壓力。關鍵藥用輔料和包裝材料的關稅提高了生產成本，迫使企業重新評估籌資策略，並與替代供應商談判合約。因此，契約製造生產商（CMO）的利潤率面臨壓力，這可能導致下游市場的價格調整。這可能會影響病人的用藥和醫保報銷談判。

為了有策略地分配資源，我們深入研究了各種細分方面，揭示了治療方法的細微差異。

對市場細分的詳細分析揭示了患者和產品屬性的差異如何影響策略重點。雖然眼藥水等製劑仍然是治療方案的基礎，但眼瞼擦拭巾和眼膏等新型產品正在滿足特定需求，尤其適用於需要在睡眠期間局部緩解症狀或進行眼表清潔的患者。儘管凝膠和噴霧劑佔據的市場佔有率較小，但它們為那些無法耐受傳統眼藥水或需要快速緩解症狀的患者提供了替代方案。

區域比較分析揭示了美洲、歐洲、中東和非洲以及亞太市場的明確促進因素、機會和挑戰。

區域趨勢對市場發展有顯著影響，每個地區在監管、經濟和患者群體方面都有其獨特的考量。在美洲，成熟的醫療基礎設施和健全的報銷體系支持高品質製劑和創新給藥系統的快速普及。臨床醫生和患者的高度認知推動了對先進治療方法的需求，而支付方則重視已證實的臨床效益和成本效益。

揭示定義乾眼症治療市場競爭領導地位的創新夥伴關係、產品線策略和永續發展舉措。

乾眼症治療領域的主要企業正透過策略性投資研發、全球擴張計畫和產品組合多元化來提升自身競爭力。一些產業先驅優先透過收購利基生物技術創新企業來豐富產品線，從而獲得獨特的免疫調節分子和先進的藥物遞送平台。另一些企業則在加強與合約研究組織（CRO）的合作，以加速臨床開發並最佳化資本配置。

乾眼症治療公司在推動創新方面面臨的策略挑戰：加強病人參與和確保供應鏈的韌性。

行業領導企業應優先考慮對下一代藥物輸送系統和新型治療方法進行有針對性的研發投資，以滿足不斷變化的患者期​​望和保險報銷標準。透過推進與數位醫療的整合，例如利用遠端醫療平台進行居家淚膜評估和藥物依從性追蹤，企業可以實現產品差異化，並進一步提升患者參與度。

結合定性專業知識和定量檢驗的綜合調查方法框架，用於乾眼症市場分析。

這項市場調查基於嚴謹且多維度的調查方法，旨在確保分析的深度和可靠性。主要研究工作包括對關鍵意見領袖（KOL）進行深入訪談，訪談對象包括眼科醫生、驗光師和醫藥經濟學專家，從而獲得關於臨床應用和報銷框架的真實觀點。此外，與產業主管的直接諮詢也讓我們深入了解了他們的策略重點、產品平臺和合作趨勢。

整合以創新、細分趨勢和區域差異為重點的關鍵研究成果，以指導未來的策略決策。

不斷發展的乾眼症治療市場呈現出技術創新、監管環境變化和患者細分日益精細化的融合趨勢。先進配方和數位健康工具的引入有望重新定義治療標準，而關稅驅動的供應鏈調整則凸顯了營運靈活性的重要性。從地理來看，市場成熟度因地區而異，從美洲高度發展的醫保體系，到亞太地區對成本高度敏感的成長型市場，再到歐洲、中東和非洲地區（EMEA）複雜的監管環境，不一而足。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 乾眼症治療市場：依產品形式分類

  • 眼藥水
  • 眼瞼濕紙巾
  • 凝膠/軟膏
  • 噴

第9章：乾眼症治療藥物市場

  • 非處方藥
  • 處方藥

第10章：乾眼症治療藥物市場

  • 抗發炎藥
  • 人工淚液
  • 免疫調節劑
  • 脂質療法

第11章 乾眼症治療市場：依最終使用者分類

  • 成人
  • 老年人
  • 兒童

第12章：依治療時間分類的乾眼症治療市場

  • 長期
  • 短期

第13章：乾眼症治療市場：依通路分類

  • 離線
    • 醫院和診所
    • 零售藥房
    • 專科診所
  • 線上

第14章 乾眼症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 乾眼症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 乾眼症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國乾眼症治療市場

第18章：中國乾眼症治療市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Harrow Health, Inc.
  • Johnson & Johnson Services, Inc.
  • Kiora Pharmaceuticals, Inc.
  • Laboratorios Sophia SA De CV
  • Nicox SA
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Wockhardt Ltd.
Product Code: MRR-1A1A064C0036

The Dry Eye Medication Market was valued at USD 5.16 billion in 2024 and is projected to grow to USD 5.49 billion in 2025, with a CAGR of 6.72%, reaching USD 7.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.16 billion
Estimated Year [2025] USD 5.49 billion
Forecast Year [2030] USD 7.62 billion
CAGR (%) 6.72%

Setting the Stage for a Comprehensive Dry Eye Medication Overview Highlighting Patient Needs Technological Advances and Regulatory Dynamics

The prevalence of dry eye disease has surged in recent years, propelled by increased digital screen usage, environmental stressors, and an aging global population. As patients increasingly seek relief from ocular discomfort, the dry eye medication landscape has become a focal point for pharmaceutical innovation and healthcare investment. Beginning with a broad understanding of underlying risk factors, this introduction maps out the current ecosystem, highlighting how multifactorial etiologies-from meibomian gland dysfunction to tear film instability-drive both clinical and commercial imperatives.

Moreover, emerging regulatory standards and patient expectations are reshaping product development priorities. With regulatory bodies emphasizing safety, efficacy, and patient-centric outcomes, manufacturers are navigating a complex framework that balances innovation with compliance. At the same time, healthcare providers are adopting minimally invasive treatment protocols, while payers demand evidence of cost-effectiveness and quality-of-life improvements. Against this backdrop, stakeholders must align strategic objectives with patient needs, ensuring that portfolios address acute symptoms and long-term ocular surface health.

In sum, this introduction sets the stage for a deeper exploration of market forces, technological breakthroughs, and policy dynamics that collectively influence the trajectory of dry eye therapies. It underscores the importance of a holistic perspective-one that integrates clinical science, commercial strategy, and patient experience-to capitalize on growth opportunities in a rapidly evolving arena.

Unprecedented Innovations and Digital Integration Driving the Next Wave of Dry Eye Therapeutic Solutions and Market Evolution

The dry eye medication landscape is witnessing transformative shifts that redefine therapeutic paradigms and market structures. Novel drug delivery platforms, such as microemulsion-based eye drops and sustained-release ocular inserts, are revolutionizing patient adherence by offering extended relief without frequent administration. Concurrently, the integration of digital health tools-ranging from smartphone-based tear film analyzers to remote monitoring platforms-enables real-time patient data collection, fostering more personalized treatment regimens.

At the same time, advancements in immunomodulatory agents are unlocking new pathways for chronic inflammation management, while lipid-based therapies are gaining traction for their capacity to restore tear film integrity. These innovations are complemented by a growing emphasis on preservative-free formulations, addressing safety concerns tied to long-term ocular surface exposure. In parallel, strategic collaborations between biotech firms and academic institutions are accelerating the translation of cutting-edge research into market-ready assets.

Meanwhile, evolving reimbursement frameworks are prompting manufacturers to demonstrate robust clinical and economic benefits, thereby influencing development timelines and go-to-market tactics. As a result, stakeholders are prioritizing real-world evidence generation and value-based contracting to secure favorable coverage decisions. Taken together, these converging forces herald a new era of patient-centric, data-driven dry eye therapeutics that promise enhanced efficacy, safety, and accessibility.

Assessing the Ripple Effects of 2025 United States Tariffs on Dry Eye Medication Supply Chains Manufacturing Costs and Global Trade Dynamics

In 2025, the implementation of new United States tariffs has introduced significant cost pressures across the dry eye medication supply chain. Tariffs on key pharmaceutical excipients and packaging materials have elevated manufacturing expenses, compelling companies to reassess sourcing strategies and negotiate alternative supplier agreements. Consequently, contract manufacturers are experiencing margin squeezes, leading to potential price adjustments downstream that may affect patient access and reimbursement negotiations.

In response, some firms are relocating production to tariff-exempt regions or investing in vertical integration to mitigate external cost volatility. These strategic shifts are accompanied by intensified risk management protocols, including dual-sourcing policies and inventory buffering, to ensure product availability amid fluctuating trade dynamics. Moreover, regulatory filings are now incorporating tariff impact assessments, reflecting a more comprehensive approach to product cost modeling.

As trade tensions evolve, market participants are also exploring local manufacturing incentives and government partnerships aimed at enhancing domestic production capacity. While such initiatives may bolster supply resilience, they require significant capital outlays and lead times. Ultimately, understanding the cumulative effects of tariff-related disruptions is critical for stakeholders intent on balancing cost containment, supply continuity, and patient affordability in a highly competitive marketplace.

Deep Dive into Diverse Segmentation Dimensions Illuminating Treatment Modalities Demographics and Distribution Nuances for Strategic Resource Allocation

A nuanced examination of market segmentation reveals how different patient and product attributes shape strategic priorities. Formulations such as eye drops remain the cornerstone of treatment regimens, but emerging options like eyelid wipes and ointments cater to specialized patient needs, particularly those requiring targeted relief during sleep or for ocular surface hygiene. Gels and sprays, though niche, offer alternatives for individuals intolerant to conventional drop instillation or seeking rapid symptomatic relief.

Diverging between over-the-counter availability and prescription-only therapies, manufacturers must tailor their promotional and distribution strategies accordingly. While artificial tears and anti-inflammatory medications dominate the retail shelf, immunomodulatory agents and lipid-based therapies occupy prescription channels, reflecting higher clinical complexity and oversight. Furthermore, the age-based segmentation of adults, geriatrics, and pediatrics underscores varying compliance challenges and dosing considerations, demanding bespoke educational and packaging features.

Treatment duration further refines the marketplace, with short-term interventions addressing acute flare-ups and long-term regimens focusing on chronic management. Finally, distribution channels-from hospital clinics and specialty centers to retail pharmacies and digital storefronts-determine outreach effectiveness and patient convenience. Offline channels benefit from clinical endorsements, whereas online platforms excel in convenience and broader geographic reach. Collectively, these segmentation dimensions illuminate nuanced growth pockets and inform targeted resource allocation across the product lifecycle.

Comparative Regional Analysis Revealing Distinct Drivers Opportunities and Challenges Spanning Americas EMEA and Asia Pacific Markets

Regional dynamics exert a profound influence on market trajectories, with each geography presenting distinct regulatory, economic, and patient profile considerations. In the Americas, mature healthcare infrastructure and robust reimbursement mechanisms support rapid adoption of premium formulations and innovative delivery systems. High awareness levels among clinicians and patients drive demand for advanced therapies, while payer frameworks reward demonstrable clinical benefits and cost-offsets.

Conversely, the Europe, Middle East & Africa region exhibits heterogeneity in regulatory pathways and economic maturity. Western European markets emphasize stringent safety and real-world evidence requirements, whereas emerging markets in the Middle East and Africa prioritize affordability and access. Navigating variable import regulations and localized pricing controls remains a key strategic focus, as does forging partnerships with regional distributors to streamline market entry.

In Asia-Pacific, rising dry eye prevalence is fueled by urbanization, pollution, and digital device proliferation. While developed markets like Japan and Australia show eagerness for next-generation therapies, cost-sensitive markets in Southeast Asia necessitate tiered pricing models and localized manufacturing alliances. Digital health adoption, particularly tele-ophthalmology platforms, is accelerating in populous markets, offering novel avenues for patient engagement and post-market support. These regional insights underscore the necessity of differentiated market strategies aligned with local healthcare dynamics.

Unveiling Innovative Partnerships Pipeline Strategies and Sustainability Initiatives Defining Competitive Leadership in Dry Eye Therapeutics

Leading companies in the dry eye medication arena are distinguished by their strategic investment in R&D, global expansion plans, and portfolio diversification. Some industry frontrunners have prioritized pipeline enrichment through acquisitions of niche biotech innovators, gaining access to proprietary immunomodulatory molecules and advanced drug delivery platforms. Others have cemented alliances with contract research organizations to expedite clinical development while optimizing capital deployment.

Simultaneously, partnerships with digital health startups are enabling select players to integrate remote monitoring solutions and personalized dosing algorithms into their offerings. Geographic expansion remains a critical theme, with firms establishing regional hubs to navigate local regulatory landscapes and bolster distribution networks. Collaboration with specialist eye clinics and ophthalmology societies further amplifies thought leadership and accelerates market penetration for cutting-edge therapies.

Furthermore, companies are increasingly focusing on sustainability and corporate responsibility, implementing eco-friendly packaging and reducing carbon footprints across manufacturing operations. Such initiatives not only resonate with stakeholder expectations but also align with emerging regulatory mandates. Overall, the competitive landscape is characterized by dynamic collaborations, technological convergence, and a relentless drive to deliver differentiated patient value.

Strategic Imperatives for Dry Eye Medication Companies to Drive Innovation Enhance Patient Engagement and Ensure Supply Chain Resilience

Industry leaders should prioritize targeted R&D investments in next-generation drug delivery systems and novel therapeutic modalities to meet evolving patient expectations and reimbursement criteria. Embracing digital health integration, including telemedicine platforms for home-based tear film assessments and adherence tracking, will differentiate offerings and foster stronger patient engagement.

Simultaneously, firms must fortify supply chain resilience by diversifying supplier portfolios and exploring localized manufacturing partnerships to mitigate tariff-induced cost fluctuations. Cultivating collaborative relationships with healthcare providers and payers through value-based contracting will support favorable formulary positioning and secure long-term revenue streams.

Moreover, adopting flexible pricing models that reflect regional economic conditions and patient affordability can unlock underserved markets, particularly in Asia-Pacific and parts of EMEA. Companies should also enhance educational outreach, leveraging digital channels and patient-support programs to elevate disease awareness and drive early intervention. By aligning product innovation, market access strategies, and operational agility, industry leaders can capitalize on emerging opportunities while mitigating potential risks in a competitive and regulatory-intensive environment.

Comprehensive Methodological Framework Integrating Qualitative Expertise and Quantitative Validation for Dry Eye Market Analysis

This market study is founded on a rigorous, multi-pronged research methodology designed to ensure analytical depth and reliability. Primary research efforts included in-depth interviews with key opinion leaders spanning ophthalmologists, optometrists, and pharmacoeconomics experts, providing real-world perspectives on clinical usage and reimbursement frameworks. Additionally, direct consultations with industry executives yielded insights into strategic priorities, product pipelines, and partnership trends.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, company annual reports, and industry white papers. Data triangulation techniques were employed to reconcile divergent information sources, while advanced statistical tools facilitated validation of qualitative findings against quantitative datasets. Segment-specific analyses were conducted via cross-tabulation of product form, drug type, medication classification, end-user demographics, treatment duration, and distribution channel variables.

Furthermore, region-specific regulatory and tariff impact assessments were integrated to contextualize market dynamics across the Americas, EMEA, and Asia-Pacific. All research outputs underwent rigorous peer review to ensure consistency, accuracy, and adherence to ethical research standards. This comprehensive approach underpins the study's actionable insights and strategic recommendations.

Synthesis of Core Findings Emphasizing Innovation Segmentation Dynamics and Regional Variances Guiding Future Strategic Decisions

The evolving dry eye medication market is characterized by a convergence of technological innovation, shifting regulatory landscapes, and nuanced patient segmentation. The introduction of advanced formulations and digital health tools promises to redefine therapeutic standards, while tariff-induced supply chain adjustments underscore the importance of operational agility. Regionally, market maturity varies from highly developed reimbursement systems in the Americas to cost-sensitive growth arenas in Asia-Pacific and regulatory complexities across EMEA.

Strategic segmentation analysis highlights the critical balance between over-the-counter accessibility and prescription-grade efficacy, as well as the imperative for tailored approaches across diverse age groups and treatment durations. Competitive dynamics are increasingly shaped by mergers and acquisitions, digital partnerships, and sustainability initiatives, reflecting a holistic value proposition that extends beyond pharmacology.

In conclusion, stakeholders that align their strategic investments with emerging trends-prioritizing innovation, patient-centricity, and supply chain resilience-will be best positioned to capture value in this rapidly transforming landscape. The insights offered herein provide a foundation for informed decision-making and long-term competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dry Eye Medication Market, by Product Form

  • 8.1. Eye Drops
  • 8.2. Eyelid Wipes
  • 8.3. Gels & Ointments
  • 8.4. Sprays

9. Dry Eye Medication Market, by Drug Type

  • 9.1. Over-The-Counter Medication
  • 9.2. Prescription Medication

10. Dry Eye Medication Market, by Medication Type

  • 10.1. Anti-inflammatory Medications
  • 10.2. Artificial Tears
  • 10.3. Immunomodulatory Agents
  • 10.4. Lipids-Based Therapy

11. Dry Eye Medication Market, by End-user

  • 11.1. Adults
  • 11.2. Geriatrics
  • 11.3. Pediatrics

12. Dry Eye Medication Market, by Treatment Duration

  • 12.1. Long Term
  • 12.2. Short Term

13. Dry Eye Medication Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Hospitals & Clinics
    • 13.1.2. Retail Pharmacies
    • 13.1.3. Specialty Clinics
  • 13.2. Online

14. Dry Eye Medication Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dry Eye Medication Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dry Eye Medication Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dry Eye Medication Market

18. China Dry Eye Medication Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Alcon Inc.
  • 19.7. Bausch + Lomb Corporation
  • 19.8. Harrow Health, Inc.
  • 19.9. Johnson & Johnson Services, Inc.
  • 19.10. Kiora Pharmaceuticals, Inc.
  • 19.11. Laboratorios Sophia S.A. De C.V.
  • 19.12. Nicox S.A.
  • 19.13. Ocugen, Inc.
  • 19.14. Ocular Therapeutix, Inc.
  • 19.15. Otsuka Pharmaceutical Co., Ltd.
  • 19.16. Santen Pharmaceutical Co., Ltd.
  • 19.17. Viatris Inc.
  • 19.18. Wockhardt Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 78. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 80. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 86. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 88. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 92. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 110. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 112. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 116. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 120. AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 124. AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. ASEAN DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. ASEAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 137. ASEAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ASEAN DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ASEAN DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. ASEAN DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 141. ASEAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. ASEAN DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 143. GCC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. GCC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 145. GCC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GCC DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. GCC DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. GCC DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 149. GCC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GCC DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. BRICS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. BRICS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 161. BRICS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. BRICS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. BRICS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. BRICS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 165. BRICS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. BRICS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 167. G7 DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. G7 DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 169. G7 DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. G7 DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. G7 DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. G7 DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 173. G7 DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. G7 DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. NATO DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 176. NATO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 177. NATO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NATO DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NATO DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NATO DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 181. NATO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NATO DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 183. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)